Cancer Research UK teams up with Teon on new cancer drug
Cancer Research UK (CRUK) has signed a collaboration agreement with Teon Therapeutics to advance early clinical development of the latter’s new cancer drug.
The focus of the agreement is Teon’s potentially first-in-class small molecule adenosine A2B receptor antagonist, TT-702.
Under the terms of the agreement, CRUK will sponsor the first-in-human Phase I/II clinical development of TT-702. This will be led by a team at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust.
The Centre for Drug Development, Teon and a team of clinical investigators led by professor Johann de Bono are currently preparing to launch the early clinical trial in the second half of 2021.
Read more: http://www.pharmatimes.com/news/cancer_research_uk_teams_up_with_teon_on_new_cancer_drug_1364446
The focus of the agreement is Teon’s potentially first-in-class small molecule adenosine A2B receptor antagonist, TT-702.
Under the terms of the agreement, CRUK will sponsor the first-in-human Phase I/II clinical development of TT-702. This will be led by a team at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust.
The Centre for Drug Development, Teon and a team of clinical investigators led by professor Johann de Bono are currently preparing to launch the early clinical trial in the second half of 2021.
Read more: http://www.pharmatimes.com/news/cancer_research_uk_teams_up_with_teon_on_new_cancer_drug_1364446
